Five additional Phase 3 studies are already enrolling behind a lead epilepsy asset that hits the FDA this quarter, which is a deeper bench than most single-catalyst biotech stories offer.

Read on for the full picture plus a health insurer trading at less than half its sector multiple.

Specialty Chemicals

H.B. Fuller Company (NYSE: FUL) trades near $61 after activist Ancora Holdings offered $1.1 billion to $1.2 billion in cash for its Building Adhesive Solutions business. At the high end, the proposal equals roughly 36% of H.B. Fuller’s entire $3.4 billion market value, even though the division represents only part of the company.

The numbers make the proposal harder to ignore. Building Adhesive Solutions generated $427 million of first-half revenue and about $63 million of segment adjusted EBITDA, while H.B. Fuller produced $181 million of adjusted EBITDA in Q2 alone. You are effectively getting a public valuation marker on one of the company’s lower-margin businesses.

H.B. Fuller also raised 2026 adjusted EBITDA guidance to $650 million to $675 million, while adjusted EPS guidance stands at $4.60 to $4.90. Near $61, the shares trade around 13 times the midpoint of adjusted earnings, giving your valuation case support even without an asset sale.

A Sale Could Attack the Debt Load

Net debt stood at $1.96 billion at the end of Q2, with leverage at 3.1 times adjusted EBITDA. If you see a deal anywhere near Ancora’s proposed price, the proceeds could materially reduce debt and leave H.B. Fuller 

focused on its higher-margin adhesive businesses.

The $1.2 Billion Number Is Not Guaranteed

Ancora’s proposal is not an agreed transaction, and selling the division would also remove its earnings contribution. The discount only closes if management can turn any asset monetization into a stronger balance sheet and better returns from the businesses that remain.

AI Infrastructure

Super Micro Computer Inc. (NASDAQ: SMCI) trades near $35.79 after fiscal 2026 revenue surged 78% to $39.1 billion and non-GAAP EPS climbed to $3.63 from $2.06. Shares jumped about 13% after management projected another major step higher in fiscal 2027.

The company now expects $65 billion to $72 billion of revenue this fiscal year, well above the roughly $52.5 billion Wall Street had expected before the report. At today’s price, you get the stock for roughly 9.9 times the adjusted earnings it just produced, despite revenue potentially approaching $70 billion.

Demand remains unusually strong. Super Micro entered the new year after receiving more than $60 billion of new orders, while Q4 gross margin improved to 17.5% from 9.5% and adjusted EBITDA reached $1.67 billion.

Growth Is Still Priced at a Discount

One analyst now expects fiscal 2027 adjusted EPS of $5.13, which would put the shares near seven times forward earnings. Your valuation case does not require that forecast to be perfect, because even trailing adjusted earnings leave Super Micro at a single-digit-to-low-double-digit multiple despite explosive AI infrastructure demand.

Cash Flow Explains the Skepticism

Operating cash flow was negative $6.8 billion in fiscal 2026 as inventory and working-capital needs expanded rapidly, while dilution and convertible financing remain concerns. If you want the low multiple to rerate, Super Micro needs to prove its huge order book can translate into cash rather than simply higher revenue.

Oil & Gas

APA Corporation (NASDAQ: APA) trades near $40 after Benchmark raised its price target to $46 from $40, citing lower costs, improving efficiency, and continued debt reduction. Even after a strong run, the stock still changes hands at roughly 8.5 times trailing earnings.

APA generated more than $1.2 billion of free cash flow during the first half, including $738 million in Q2. Management plans roughly $900 million of second-half share repurchases, equal to more than 6% of the current market value, giving your valuation case a direct per-share catalyst.

Net debt has fallen to about $3.3 billion after APA repaid $2.3 billion since the end of 2024. Those repayments have eliminated more than $155 million of annualized interest expense, so you have improving financial flexibility alongside the low earnings multiple.

Buybacks Follow the Debt Cleanup

APA already repurchased about $99 million of stock during Q2, and the larger second-half program comes as leverage approaches management’s $3 billion net-debt target. Lower interest costs and fewer shares can push more free cash flow toward each remaining shareholder without requiring faster production growth.

Oil Prices Still Control the Math

Production fell nearly 12% year over year in Q2, while stronger commodity prices helped protect cash generation. If you want the sub-9x multiple to rerate, APA has to keep producing strong free cash flow even when oil prices provide less support.

Progressive (NYSE: PGR) Progressive has fallen roughly 24% over the past year while earnings per share compounded at about 44% annually across the last three years. That is a divergence that eventually resolves, and Q2 gave no reason to think the business is the problem, with EPS beating estimates by nearly 7% on revenue up 7.3%. Now the honest part: the models disagree sharply.

The Excess Returns framework puts intrinsic value far above the current price, while a straight P/E comparison shows 11.1x sitting slightly above both the fair ratio of 10.6x and the peer average of 9.3x. You are buying the earnings trajectory, not a screaming multiple discount, and you should know which of those two things you are underwriting.

Insmed (NASDAQ: INSM) Insmed reported Q2 revenue above expectations on August 6, and GF Value pegs the stock as roughly 47% undervalued. That is the bull case, and it is real. The bear case is on the same page: price-to-sales sits at 25.44 against the company’s own historical median of 18.19, meaning it is more expensive than its own history on the only multiple that applies to an unprofitable business.

The Brinsupri launch is genuinely happening at pace, and guidance raises this early usually mean the ramp is holding rather than frontloading. Treat this as growth at an inflection rather than a discount, because that is what it is. The risk is competitive entry or reimbursement friction slowing the curve before the guidance range is proven.

Green Plains (NASDAQ: GPRE) trades at about 8.5 times earnings against an Oil and Gas industry average near 13.1 times and a peer group at 20.8 times. Here is what the screeners will not tell you. The analyst price target is $14.00, and the stock closed recently at $14.97.

It has been trading above the widely followed fair value, and at least one analyst position is explicitly to take profits after a rally exceeding 65% year-to-date. Against the industry multiple, this is inexpensive. Against where analysts think it should trade, it is roughly at fair value. Which framing matters depends on your holding period.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge